TACE with Icaritin after surgery for high-risk liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining a targeted medicine (Icaritin) with a procedure that delivers chemotherapy directly to the liver (TACE) after surgery. It is for people with liver cancer who have a high chance of the cancer coming back, to see if this treatment helps prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- You must have been diagnosed with hepatocellular carcinoma (a type of liver cancer)
- You must have had surgery that removed all visible cancer (called R0 resection) 4 to 8 weeks ago
- Your cancer must have at least one high-risk feature, such as a large tumor (5 cm or more), multiple tumors, blood vessel invasion, or low cell differentiation
- You must be in generally good health (ECOG score 0-1) and have good liver function (Child-Pugh score 5-6)
- You cannot have had any other cancer treatment for liver cancer before, except for up to two preventive TACE or HAIC treatments after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This trial tests whether taking icariin soft capsules along with a liver-directed treatment called TACE can help prevent liver cancer from coming back after surgery or ablation. It is for people who have had their tumor removed but still have risk factors that make recurrence more likely.
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.